世界の異常ヘモグロビン症市場2021-2028:種類別(サラセミア、鎌状赤血球症、その他ヘモグロビン(Hb)変異体)、診断別、治療別、地域別

◆英語タイトル:Hemoglobinopathies Market Size, Share & Trends Analysis Report By Type (Thalassemia, Sickle Cell Disease, Other Hemoglobin (Hb) Variants), By Diagnosis, By Therapy, By Region, And Segment Forecasts, 2021 - 2028
◆商品コード:GV21MC037
◆発行会社(リサーチ会社):Grand View Research
◆発行日:2021年2月26日
◆ページ数:120
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥678,300見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算¥792,300見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算¥1,020,300見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGrand View Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Grand View Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

グランドビューリサーチ社は、世界の異常ヘモグロビン症市場規模が2028年までに157憶ドルに達すると予測しています。2021年から2028年までに年平均10.8%成長する見通しです。本調査レポートでは、異常ヘモグロビン症の世界市場について調査・分析し、調査手法・範囲、エグゼクティブサマリー、市場変動・動向・範囲、種類別(サラセミア、鎌状赤血球症、その他ヘモグロビン(Hb)変異体)分析、診断別(サラセミア診断、鎌状赤血球症診断、その他ヘモグロビン(Hb)変異体診断)分析、治療別(サラセミア治療、鎌状赤血球症治療、その他ヘモグロビン(Hb)変異体治療)分析、地域別分析、競争分析などを掲載しています。
・調査手法・範囲
・エグゼクティブサマリー
・市場変動・動向・範囲
・異常ヘモグロビン症の世界市場規模:種類別(サラセミア、鎌状赤血球症、その他ヘモグロビン(Hb)変異体)
・異常ヘモグロビン症の世界市場規模:診断別(サラセミア診断、鎌状赤血球症診断、その他ヘモグロビン(Hb)変異体診断)
・異常ヘモグロビン症の世界市場規模:治療別(サラセミア治療、鎌状赤血球症治療、その他ヘモグロビン(Hb)変異体治療)
・異常ヘモグロビン症の世界市場規模:地域別
・競争分析
【レポートの概要】

Hemoglobinopathies Market Growth & Trends

The global hemoglobinopathies market size is expected to reach USD 15.7 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 10.8% from 2021 to 2028. Increasing awareness regarding hemoglobinopathies and government initiatives to diagnose the diseases at an early stage are expected to propel the market growth over the forecast period. Moreover, increasing R&D investment, the presence of a promising drug pipeline, and technologically advanced diagnostics platforms are expected to boost the growth of the market.

The development of novel curative technologies, such as CRISPR/Cas9 and hematopoietic stem cell transplantation, coupled with a promising pipeline, is expected to propel market growth. Moreover, the presence of regulatory agencies, such as the FDA, which are working toward improving drug approval rate by granting accelerated approval for hemoglobinopathies drugs, is expected to drive the market. For instance, in 2019, the FDA has approved four novel drugs: Reblozyl by Bristol-Myers Squibb Company, Adakveo by Novartis AG, Zynteglo by bluebird bio, Inc., and Oxbryta by Global Blood Therapeutics, Inc. for the treatment of hemoglobinopathies.

Initiatives such as the Sickle Cell Awareness Initiative (SCAI) are working toward educating the people about the disease, which will increase the diagnosis and treatment rate. SCAI also raises funds for individuals affected with sickle cell diseases (SCDs) and provides research funding. Moreover, governments of Middle Eastern and Asian countries provide funds for R&D of hemoglobinopathies treatment. For instance, various programs undertaken by governments, such as thalassemia screening in neonates and providing medicines, are impacting the market growth positively.

The high patient population in low-income countries has encouraged market players and non-profit organizations to launch several initiatives to improve the access to the therapy. For instance, in February 2019, the Access to Excellent Care for Sickle Cell Patients Pilot Program (ACCEL) was launched by Global Blood Therapeutics, Inc. in order to provide research funding for novel SCD projects, with an aim to expand the access to optimal healthcare for sickle cell disease.

Biopharmaceutical companies are collaborating with nonprofit organizations to promote public awareness about hemoglobinopathies. For instance, in June 2018, the Sickle Cell Disease Association of America partnered with Emmaus Life Sciences, Inc. to provide online educational tools to sickle cell patients, friends, clinicians, caregivers, and researchers for spreading awareness about complications associated with SCD.

An increase in investment and funding for the development of novel therapies to treat hemoglobinopathies will further boost the market growth over the forecast period. The National Heart, Lung, and Blood Institute (NHLBI) has significantly invested in research & development in sickle cell disease. The NHLBI supports research work through various initiatives. Furthermore, private funding such as the Bronx Blood Research Fund (BBRF) provides a platform for research and management of thalassemia and other hemoglobinopathies.

Gene therapy has emerged as a promising treatment option for managing hemoglobin disorder as it targets the underlying genetic cause of the condition through the administration of one-time gene therapy and significantly reduces the need for blood transfusions. The current pipeline of gene therapy products includes CTX001 (CRISPR Therapeutics), BIVV003 (Sangamo Therapeutics, Inc. & Bioverativ Inc), and HGB-206 (bluebird bio, Inc).

Hemoglobinopathies Market Report Highlights

• Based on type, sickle cell disease accounted for the largest share of 56.6% in 2020 and is anticipated to maintain its lead over the forecast period

• The newborn patient population with sickle cell anemia is anticipated to reach 400,000 by 2050. Half of the global sickle cell anemia burden is present in India, Nigeria, and the Democratic Republic of the Congo

• By therapy, in the thalassemia segment, the blood transfusion segment held the largest market share in 2020 and is estimated to dominate the market throughout the forecast period

• Asia Pacific is expected to witness the fastest growth over the forecast period owing to a large potential patient base and high unmet medical needs in the region

• North America held the largest market share in 2020 due to government initiatives focusing on the development of new therapies and better reimbursement scenario

【レポートの目次】

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation
1.1.1 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country-wise Market Estimation Using Bottom-Up Approach
1.7 Global Market: CAGR Calculation
1.8 Research Assumptions
1.9 List of Secondary Sources
1.10 Objectives
1.10.1 Objective 1:
1.10.2 Objective 2:
1.11 List of Abbreviations
Chapter 2 Executive Summary
2.1 Market Summary
Chapter 3 Global Hemoglobinopathies Market Variables, Trends & Scope
3.1 Penetration and Growth Prospect Mapping
3.2 Epidemiology Assessment of Hemoglobinopathies
3.2.1 Sickle cell disease
3.2.2 Thalassemia
3.3 Market Variable Analysis
3.3.1 Increasing prevalence of hemoglobinopathies in under-developed countries
3.3.2 High unmet needs
3.3.3 Increasing R&D investment
3.3.4 Initiatives to improve disease awareness levels
3.4 Market Restraint Analysis
3.4.1 Lack of healthcare infrastructure
3.4.2 High cost of treatment
3.5 SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
3.6 Porter’s Five Forces Analysis
Chapter 4 Hemoglobinopathies Market – Segment Analysis, by Type, 2017 – 2028 (USD Million)
4.1 Market: Type Movement Analysis
4.2 Thalassemia
4.2.1 Market estimates and forecast, 2017 – 2028 (USD Million)
4.2.2 Alpha Thalassemia
4.2.3 Beta thalassemia
4.3 Sickle Cell Disease
4.3.1 Market estimates and forecast, 2017 – 2028 (USD Million)
4.4 Other Hemoglobin (Hb) Variants
4.4.1 Market estimates and forecast, 2017 – 2028 (USD Million)
Chapter 5 Hemoglobinopathies Market – Segment Analysis, by Diagnosis, 2017 – 2028 (USD Million)
5.1 Hemoglobinopathies Market: Diagnosis Movement Analysis
5.2 Thalassemia Diagnosis
5.2.1 Thalassemia diagnosis market estimates and forecast, 2017 – 2028 (USD Million)
5.2.2 Blood Test
5.2.3 Genetic Test
5.2.4 Prenatal Genetic Test
5.2.5 Pre-implantation Genetic Diagnosis
5.2.6 Electrophoresis
5.2.7 Others
5.3 Sickle Cell Disease Diagnosis
5.3.1 Sickle cell disease diagnosis market estimates and forecast, 2017 – 2028 (USD Million)
5.3.2 Blood Test
5.3.3 Genetic Test
5.3.4 Prenatal Genetic Test
5.3.5 Electrophoresis
5.3.6 Others
5.4 Other Hemoglobin (Hb) Variants Diagnosis
5.4.1 Other hemoglobin (Hb) variants diagnosis market estimates and forecast, 2017 – 2028 (USD Million)
5.4.2 Blood Test
5.4.3 Genetic Test
5.4.4 Prenatal Genetic Test
5.4.5 Electrophoresis
5.4.6 Others
Chapter 6 Hemoglobinopathies Market – Segment Analysis, by Therapy, 2017 – 2028 (USD Million)
6.1 Hemoglobinopathies Market: Therapy Movement Analysis
6.2 Thalassemia Therapy
6.2.1 Thalassemia therapy market estimates and forecast, 2017 – 2028 (USD Million)
6.2.2 Blood Transfusion
6.2.3 Iron Chelation Therapy
6.2.4 Bone Marrow Transplant
6.2.5 Others
6.3 Sickle Cell Disease Therapy
6.3.1 Sickle cell disease therapy market estimates and forecast, 2017 – 2028 (USD Million)
6.3.2 Blood Transfusion
6.3.3 Hydroxyurea
6.3.4 Bone Marrow Transplant
6.3.5 Others
6.4 Other Hemoglobin (Hb) Variants Therapy
6.4.1 Other hemoglobin (Hb) variants therapy market estimates and forecast, 2017 – 2028 (USD Million)
6.4.2 Blood Transfusion
6.4.3 Hydroxyurea
6.4.4 Iron Chelation Therapy
6.4.5 Bone Marrow Transplant
6.4.6 Others
Chapter 7 Hemoglobinopathies Market – Segment Analysis, by Region, 2017 – 2028 (USD Million)
7.1 Hemoglobinopathies Market: Regional Movement Analysis
7.2 North America
7.2.1 North America market estimates and forecast, 2017 – 2028 (USD Million)
7.2.2 U.S.
7.2.2.1 U.S. market estimates and forecast, 2017 – 2028 (USD Million)
7.3 Canada
7.3.1.1 Canada market estimates and forecast, 2017 – 2028 (USD Million)
7.4 Europe
7.4.1 Europe market estimates and forecast, 2017 – 2028 (USD Million)
7.4.2 U.K.
7.4.2.1 U.K. market estimates and forecast, 2017 – 2028 (USD Million)
7.4.3 Germany
7.4.3.1 Germany market estimates and forecast, 2017 – 2028 (USD Million)
7.4.4 France
7.4.4.1 France market estimates and forecast, 2017 – 2028 (USD Million)
7.4.5 Italy
7.4.5.1 Italy market estimates and forecast, 2017 – 2028 (USD Million)
7.4.6 Spain
7.4.6.1 Spain market estimates and forecast, 2017 – 2028 (USD Million)
7.4.7 Russia
7.4.7.1 Russia market estimates and forecast, 2017 – 2028 (USD Million)
7.5 Asia Pacific
7.5.1 Asia Pacific market estimates and forecast, 2017 – 2028 (USD Million)
7.5.2 Japan
7.5.2.1 Japan market estimates and forecast, 2017 – 2028 (USD Million)
7.5.3 China
7.5.3.1 China market estimates and forecast, 2017 – 2028 (USD Million)
7.5.4 India
7.5.4.1 India market estimates and forecast, 2017 – 2028 (USD Million)
7.5.5 South Korea
7.5.5.1 South Korea market estimates and forecast, 2017 – 2028 (USD Million)
7.5.6 Singapore
7.5.6.1 Singapore market estimates and forecast, 2017 – 2028 (USD Million)
7.5.7 Australia
7.5.7.1 Australia market estimates and forecast, 2017 – 2028 (USD Million)
7.6 Latin America
7.6.1 Latin America market estimates and forecast, 2017 – 2028 (USD Million)
7.6.2 Brazil
7.6.2.1 Brazil market estimates and forecast, 2017 – 2028 (USD Million)
7.6.3 Mexico
7.6.3.1 Mexico market estimates and forecast, 2017 – 2028 (USD Million)
7.6.4 Argentina
7.6.4.1 Argentina market estimates and forecast, 2017 – 2028 (USD Million)
7.7 Middle East & Africa
7.7.1 Middle East & Africa market estimates and forecast, 2017 – 2028 (USD Million)
7.7.2 South Africa
7.7.2.1 South Africa market estimates and forecast, 2017 – 2028 (USD Million)
7.7.3 United Arab Emirates
7.7.3.1 United Arab Emirates market estimates and forecast, 2017 – 2028 (USD Million)
7.7.4 Saudi Arabia
7.7.4.1 Saudi Arabia market estimates and forecast, 2017 – 2028 (USD Million)
Chapter 8 Competitive Analysis
8.1 Recent Developments & Impact Analysis, by Key Market Participants
8.1.1 Ansoff matrix
8.1.2 Company/Competition Categorization (Key innovators, Market leaders, Expansion)
8.1.3 Innovators
8.1.4 Market Leaders
8.2 Vendor Landscape
8.2.1 List of key distributors and channel partners
8.2.2 Key customers
8.2.3 Strategic framework
8.3 Major Deals and Strategic Alliances Analysis
8.3.1.1 New product launch
8.3.1.2 Mergers and acquisitions
8.3.1.3 Expansion
8.3.1.4 Partnerships
8.3.1.5 Marketing & promotions
8.4 Company Profiles
8.4.1 Sangamo Therapeutics
8.4.1.1 Company overview
8.4.1.2 Financial performance
8.4.1.3 Product benchmarking
8.4.1.4 Strategic initiatives
8.4.2 bluebird bio, Inc.
8.4.2.1 Company overview
8.4.2.2 Financial performance
8.4.2.3 Product benchmarking
8.4.2.4 Strategic initiatives
8.4.3 Global Blood Therapeutics, Inc.
8.4.3.1 Company overview
8.4.3.2 Financial performance
8.4.3.3 Product benchmarking
8.4.3.4 Strategic initiatives
8.4.4 Pfizer, Inc.
8.4.4.1 Company overview
8.4.4.2 Financial performance
8.4.4.3 Product benchmarking
8.4.4.4 Strategic initiatives
8.4.5 Emmaus Life Sciences, Inc.
8.4.5.1 Company overview
8.4.5.2 Financial performance
8.4.5.3 Product benchmarking
8.4.5.4 Strategic initiatives
8.4.6 Prolong Pharmaceuticals, LLC
8.4.6.1 Company overview
8.4.6.2 Product benchmarking
8.4.6.3 Strategic initiatives
8.4.7 Celgene Corporation (BMS)
8.4.7.1 Company overview
8.4.7.2 Financial performance
8.4.7.3 Product benchmarking
8.4.7.4 Strategic initiatives
8.4.8 Bioverativ Inc. (Sanofi)
8.4.8.1 Company overview
8.4.8.3 Product benchmarking
8.4.8.4 Strategic initiatives
8.4.9 Gamida Cell
8.4.9.1 Company overview
8.4.9.2 Financial performance
8.4.9.3 Product benchmarking
8.4.9.4 Strategic initiatives
8.4.10 Novartis AG
8.4.10.1 Company overview
8.4.10.2 Financial Performance
8.4.10.3 Product Benchmarking
8.4.10.4 Strategic initiatives

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 Descriptive Analysis of the Age at Diagnosis Laboratory Evaluation of Hbs, Hbf, and Hemolytic State and Complications Recorded
Table 4 List Of Normal Human Hemoglobin
Table 5 Hemoglobinopathies Market: Product Pipeline
Table 6 Leading Market Players Anticipated to Witness Highest Growth
Table 7 North America Hemoglobinopathies Market, By Country, 2017 - 2028 (USD Million)
Table 8 North America Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 9 North America Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 10 North America Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 11 U.S. Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 12 U.S. Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 13 U.S. Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 14 Canada Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 15 Canada Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 16 Canada Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 17 Europe Hemoglobinopathies Market, By Country, 2017 - 2028 (USD Million)
Table 18 Europe Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 19 Europe Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 20 Europe Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 21 U.K. Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 22 U.K. Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 23 U.K. Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 24 Germany Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 25 Germany Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 26 Germany Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 27 France Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 28 France Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 29 France Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 30 Spain Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 31 Spain Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 32 Spain Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 33 Italy Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 34 Italy Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 35 Italy Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 36 Russia Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 37 Russia Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 38 Russia Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 39 Asia Pacific Hemoglobinopathies Market, By Country, 2017 - 2028 (USD Million)
Table 40 Asia Pacific Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 41 Asia Pacific Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 42 Asia Pacific Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 43 Japan Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 44 Japan Hemoglobinopathies Market, By Diagnosis 2017 - 2028 (USD Million)
Table 45 Japan Hemoglobinopathies Market, By Therapy 2017 - 2028 (USD Million)
Table 46 China Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 47 China Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 48 China Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 49 India Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 50 India Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 51 India Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 52 South Korea Hemoglobinopathies Market, By Type 2017 - 2028 (USD Million)
Table 53 South Korea Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 54 South Korea Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 55 Singapore Hemoglobinopathies Market, By Type 2017 - 2028 (USD Million)
Table 56 Singapore Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 57 Singapore Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 58 Australia Hemoglobinopathies Market, By Type 2017 - 2028 (USD Million)
Table 59 Australia Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 60 Australia Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 61 Latin America Hemoglobinopathies Market, By Country, 2017 - 2028 (USD Million)
Table 62 Latin America Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 63 Latin America Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 64 Latin America Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 65 Brazil Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 66 Brazil Hemoglobinopathies Market, By Diagnosis 2017 - 2028 (USD Million)
Table 67 Brazil Hemoglobinopathies Market, By Therapy 2017 - 2028 (USD Million)
Table 68 Mexico Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 69 Mexico Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 70 Mexico Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 71 Argentina Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 72 Argentina Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 73 Argentina Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 74 Middle East & Africa Hemoglobinopathies Market, By Country, 2017 - 2028 (USD Million)
Table 75 Middle East & Africa Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 76 Middle East & Africa Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 77 Middle East & Africa Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 78 South Africa Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 79 South Africa Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 80 South Africa Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 81 Saudi Arabia Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 82 Saudi Arabia Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 83 Saudi Arabia Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 84 United Arab Emirates Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 85 United Arab Emirates Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 86 United Arab Emirates Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)

List of Figures

Fig. 1 Hemoglobinopathies market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Hemoglobinopathies market snapshot
Fig. 10 Penetration and growth prospect mapping
Fig. 11 Hemoglobinopathies market driver impact
Fig. 12 Prevalence of hemoglobinopathies gene carriers
Fig. 13 Hemoglobinopathies market restraint impact
Fig. 14 SWOT analysis, by factor (political & legal, economic, and technological)
Fig. 15 Porter’s five forces analysis
Fig. 16 Hemoglobinopathies market: Type outlook and key takeaways
Fig. 17 Hemoglobinopathies market: Type movement analysis
Fig. 18 Thalassemia market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 19 Sickle cell disease market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 20 Other hemoglobin (Hb) variants market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 21 Hemoglobinopathies market: Diagnosis outlook and key takeaways
Fig. 22 Hemoglobinopathies market: Diagnosis movement analysis
Fig. 23 Thalassemia diagnosis market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 24 Sickle cell disease diagnosis market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 25 Other hemoglobin (Hb) variants diagnosis market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 26 Hemoglobinopathies market: Therapy outlook and key takeaways
Fig. 27 Hemoglobinopathies market: Therapy movement analysis
Fig. 28 Thalassemia therapy market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 29 Sickle cell disease therapy market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 30 Other hemoglobin (Hb) variants therapy market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 31 Hemoglobinopathies market: Regional outlook and key takeaways
Fig. 32 Hemoglobinopathies market: Regional movement analysis
Fig. 33 North America
Fig. 34 North America market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 35 U.S.
Fig. 36 U.S. market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 37 Canada
Fig. 38 Canada market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 39 Europe
Fig. 40 Europe market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 41 U.K.
Fig. 42 U.K. market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 43 Germany
Fig. 44 Germany market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 45 France
Fig. 46 France market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 47 Italy
Fig. 48 Italy market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 49 Spain
Fig. 50 Spain market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 51 Russia
Fig. 52 Russia market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 53 Asia Pacific
Fig. 54 Asia Pacific market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 55 Japan
Fig. 56 Japan market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 57 China
Fig. 58 China market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 59 India
Fig. 60 India market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 61 South Korea
Fig. 62 South Korea market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 63 Singapore
Fig. 64 Singapore market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 65 Australia
Fig. 66 Australia market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 67 Latin America
Fig. 68 Latin America market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 69 Brazil
Fig. 70 Brazil market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 71 Mexico
Fig. 72 Mexico market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 73 Argentina
Fig. 74 Argentina market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 75 Middle East & Africa
Fig. 76 Middle East & Africa market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 77 South Africa
Fig. 78 South Africa market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 79 United Arab Emirates
Fig. 80 United Arab Emirates market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 81 Saudi Arabia
Fig. 82 Saudi Arabia market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 83 Ansoff Matrix
Fig. 84 Competition categorization
Fig. 85 Strategic framework
Fig. 86 Strategy mapping

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界の異常ヘモグロビン症市場2021-2028:種類別(サラセミア、鎌状赤血球症、その他ヘモグロビン(Hb)変異体)、診断別、治療別、地域別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆